Nicotine replacement: a new approach to reducing tobacco-related harm

Primary prevention is usually regarded as the most desirable goal in efforts to control tobacco-related diseases. However, this has not been very effective so far; moreover, it would take 30-40 yrs for primary prevention to translate into major health benefits. Modification of tobacco products and/or reduction of tobacco use may also have some impact on tobacco-related diseases. A tobacco dose-dependent risk has been observed in these diseases, including cancer, cardiovascular diseases, chronic nonspecific respiratory disorders, and problems during pregnancy. Reduced smoking (smoking fewer cigarettes, leading to a reduced intake of toxic substances) may be indicated in individuals who: 1) are failing in cessation attempts; 2) want to quit but are unable to do so; and 3) do not want to quit but want to reduce smoking. Studies have shown that nicotine replacement medications may be an untapped source in efforts to reduce smoking. Based on Austrian data, it is estimated that, approximately 10 yrs after implementation, a 1% reduction in smoking could save 14 male lung cancer deaths each year, and a 50% reduction would save 700 male lives. Inclusion of females and other tobacco-related diseases suggest that thousands of lives could be saved if smoking could be reduced by 50%. In the European Union, such a reduction in smoking could save > or = 100,000 lives annually. Even a 1% reduction would save 1,000 lives. In conclusion, reduced smoking should be explored as a valid method of reducing tobacco-related harm in those unwilling or unable to quit smoking.

This article has been cited by other articles:

				N. S. Godtfredsen, C. Holst, E. Prescott, J. Vestbo, and M. Osler Smoking Reduction, Smoking Cessation, and Mortality: A 16-year Follow-up of 19,732 Men and Women from the Copenhagen Centre for Prospective Population Studies Am. J. Epidemiol., December 1, 2002; 156(11): 994 - 1001. [Abstract] [Full Text] [PDF]

				K. O Fagerström, J. R Hughes, T. Rasmussen, and P. W Callas Randomised trial investigating effect of a novel nicotine delivery device (Eclipse) and a nicotine oral inhaler on smoking behaviour, nicotine and carbon monoxide exposure, and motivation to quit Tob. Control, September 1, 2000; 9(3): 327 - 333. [Abstract] [Full Text]

				C. T Bolliger, J.-P. Zellweger, T. Danielsson, X. van Biljon, A. Robidou, A. Westin, A. P Perruchoud, and U. Säwe Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety BMJ, August 5, 2000; 321(7257): 329 - 333. [Abstract] [Full Text]

				D Balfour, N Benowitz, K Fagerstrom, M Kunze, and U Keil Diagnosis and treatment of nicotine dependence with emphasis on nicotine replacement therapy. A status report Eur. Heart J., March 2, 2000; 21(6): 438 - 445. [Abstract] [PDF]

				J. PRIGNOT A tentative illustration of the smoking initiation and cessation cycles Tob. Control, March 1, 2000; 9(1): 113 - 113. [Full Text] [PDF]

				J. R. Hughes, M. G. Goldstein, R. D. Hurt, and S. Shiffman Recent Advances in the Pharmacotherapy of Smoking JAMA, January 6, 1999; 281(1): 72 - 76. [Abstract] [Full Text] [PDF]